🇺🇸 FDA
Pipeline program

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Lisdexamfetamine Dimesylate capsules 70 mg, manufactured by Sun Pharmaceutical Industries Limited, India with VENVANSE (lisdexamfetamine dimesylate) 70 mg Hard Gelatin Capsule, imported and registered by: Takeda Pharma Ltd. Rodovia SP 340 S/N, km 133.5, Ed. Adm. Jaguariúna-SP CNPJ 60.397.775/0001-74 and manufactured by: Patheon Pharmaceuticals Inc. Cincinnati, United States o

LISDE-01-25

Phase 1 other active

Quick answer

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Lisdexamfetamine Dimesylate capsules 70 mg, manufactured by Sun Pharmaceutical Industries Limited, India with VENVANSE (lisdexamfetamine dimesylate) 70 mg Hard Gelatin Capsule, imported and registered by: Takeda Pharma Ltd. Rodovia SP 340 S/N, km 133.5, Ed. Adm. Jaguariúna-SP CNPJ 60.397.775/0001-74 and manufactured by: Patheon Pharmaceuticals Inc. Cincinnati, United States o for ADHD (Attention Deficit Hyperactivity Disorder), BED (Binge Eating Disorder) is a Phase 1 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
ADHD (Attention Deficit Hyperactivity Disorder), BED (Binge Eating Disorder)
Phase
Phase 1
Modality
other
Status
active

Clinical trials